Han Bing, Shi Yuan-kai, Zhu Jun, He Xiao-hui, Lin Ning-jing, Li Shu-lan, Shen Ti
Department of Hematology, Peking Union Medical College Hospital, Beijing, China.
Zhonghua Xue Ye Xue Za Zhi. 2006 Aug;27(8):543-5.
To study whether hematologic malignancy patients with anemia have a lower erythropoietin (EPO) response.
Serum EPO levels were detected by ELISA in patients with hematologic malignancies and with iron deficiency anemia (IDA). Eighty patients with hematologic malignancies, including 13 multiple myeloma (MM), 7 chronic lymphocytic leukemia (CLL) and 60 non-Hodgkin's lymphoma (NHL) were studied. Thirty of them had anemia(21 NHL,6 MM and 3 CLL). Twenty patients with IDA were studied as the control.
Hematologic malignancy patients with anemia had higher EPO levels [(97.8 +/- 183.9) IU/L] than those with normal Hb values [(27.8 +/- 85.4) IU/L; P <0.01]. In patients with IDA, serum EPO response was inversely correlated with Hb level (r= -0.5, P <0.05) , but no such inverse correlation was found in the hematologic malignancy patients with anemia (r = -0.14). After corrected for Hb level, the serum EPO levels were significantly lower in anemic patients with hematologic malignancies than in IDA patients (P = 0.032) , indicating a decreased EPO response in the former group.
Anemia associated with hematologic malignancy might result from an inappropriately low EPO response. EPO treatment for these patients may be beneficial.
研究血液系统恶性肿瘤伴贫血患者的促红细胞生成素（EPO）反应是否较低。
采用酶联免疫吸附测定法（ELISA）检测血液系统恶性肿瘤患者及缺铁性贫血（IDA）患者的血清EPO水平。研究了80例血液系统恶性肿瘤患者，其中包括13例多发性骨髓瘤（MM）、7例慢性淋巴细胞白血病（CLL）和60例非霍奇金淋巴瘤（NHL）。他们中有30例贫血（21例NHL、6例MM和3例CLL）。研究了20例IDA患者作为对照。
血液系统恶性肿瘤伴贫血患者的EPO水平[（97.8±183.9）IU/L]高于血红蛋白值正常的患者[（27.8±85.4）IU/L；P<0.01]。在IDA患者中，血清EPO反应与血红蛋白水平呈负相关（r=-0.5，P<0.05），但在血液系统恶性肿瘤伴贫血患者中未发现这种负相关（r=-0.14）。校正血红蛋白水平后，血液系统恶性肿瘤贫血患者的血清EPO水平显著低于IDA患者（P=0.032），表明前一组的EPO反应降低。
血液系统恶性肿瘤相关贫血可能是由于EPO反应过低所致。对这些患者进行EPO治疗可能有益。
